KOLIGO THERAPEUTICS
Koligo Therapeutics’ mission is to develop, manufacture, and commercialize transformative cell therapies for the treatment of pancreatic diseases.Koligo is dedicated to supporting their mission while respecting their values.Their employees agree in writing to certain professional standards to codify our mutual understanding of Koligo’s ethics and conduct .
KOLIGO THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Louisville, Kentucky, United States
Country:
United States
Website Url:
http://www.kyslecel.com
Total Employee:
1+
Status:
Active
Contact:
40202 1-502-242-5890
Email Addresses:
[email protected]
Total Funding:
3.65 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail ReCAPTCHA GoDaddy DNS ReCAPTCHA V2 AWS Global Accelerator WPForms
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
Bergen Asset Management
Bergen Asset Management investment in Post-IPO Debt - Koligo therapeutics
Official Site Inspections
http://www.kyslecel.com Semrush global rank: 6.73 M Semrush visits lastest month: 840
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Koligo therapeutics"
KYSLECELâ„¢ (autologous pancreatic islets) - LinkedIn
KYSLECELâ„¢ (autologous pancreatic islets) is a transformative cell therapy for pancreatic diseases. The process includes a total pancreatectomy (removal of the pancreas) with islet …See details»
Koligo introduces KYSLECEL™ autologous cell therapy …
Aug 22, 2018 KYSLECEL is a minimally-manipulated autologous cell-based product regulated by the FDA solely under section 361 of the PHS Act and 21 …See details»
Orgenesis Announces Agreement to Acquire Koligo Therapeutics, …
The KYSLECEL pilot program has generated approximately $2 million in sales revenue. KYSLECEL has also been shown to result in significant savings to payors over traditional …See details»
Autologous pancreatic islets (Koligo) - Drug Targets, Indications ...
Autologous pancreatic islets (Koligo): a Cell replacements Drug, Initially developed by Koligo Therapeutics, Inc., Now, its global highest R&D status is Approved ...See details»
Orgenesis Announces Agreement to Acquire Koligo
The KYSLECEL pilot program has generated approximately $2 million in sales revenue. KYSLECEL has also been shown to result in significant savings to payors over traditional …See details»
Orgenesis acquires cell therapy specialist Koligo - Bioprocess Insider
Oct 2, 2020 Koligo possesses one commercially-available treatment, in the form of Kyslecel, which is an autologous pancreatic islet cell therapy used to treat chronic or recurrent acute …See details»
Orgenesis to merge with regenerative medicine company Koligo ...
Sep 29, 2020 Koligo has commenced its commercial pilot program for Kyslecel at six U.S. hospitals, treating 40 patients to date and generating about $2 million in sales revenue. …See details»
Koligo therapeutics - Crunchbase Company Profile & Funding
Koligo Therapeutics’ mission is to develop, manufacture, and commercialize transformative cell therapies for the treatment of pancreatic diseases.Koligo is dedicated to supporting their …See details»
Orgenesis Completes Acquisition of Koligo Therapeutics and
Oct 19, 2020 One of our first goals is to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in …See details»
Koligo introduces KYSLECEL™ autologous cell therapy …
Aug 22, 2018 KYSLECEL is a minimally-manipulated autologous cell-based product regulated by the FDA solely under section 361 of the PHS Act and 21 CFR Part 1271. The need for KYSLECELSee details»
Orgenesis Completes Acquisition of Koligo Therapeutics and …
Oct 19, 2020 One of our first goals is to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in …See details»
Koligo introduces KYSLECEL(TM) autologous cell therapy product
KYSLECEL may be covered by commercial health insurance, most Medicaid carriers, and Veterans Affairs. Patients must check with their physician and insurance provider for eligibility. …See details»
KOLIGO THERAPEUTICS: Introduces KYSLECEL™ autologous cell …
Aug 23, 2018 KYSLECEL is a minimally-manipulated autologous cell-based product regulated by the FDA solely under section 361 of the PHS Act and 21 CFR Part 1271. The need for …See details»
An Industrialization Strategy For Cell Therapies - Outsourced Pharma
Dec 29, 2022 Kyslecel was licensed by Orgenesis out of a university, and originally developed by a small biotech. ... Caplan clarifies that Orgenesis itself is not a marketing organization. The …See details»
Koligo introduces KYSLECEL(TM) autologous cell therapy product
Aug 23, 2018 KYSLECEL is intended to preserve insulin secretory capacity in chronic or acute recurrent pancreatitis patients after total pancreatectomy (TP-IAT). ... This material from the …See details»
KYSLECEL™ with 24-hour expiration time improves access to …
Jul 16, 2019 KYSLECEL is a minimally-manipulated autologous cell-based product available in the United States and regulated by the FDA under section 361 of the PHS Act. KYSLECEL is …See details»
Koligo introduces KYSLECELâ„¢ autologous cell therapy product
Aug 22, 2018 KYSLECEL is intended to preserve insulin secretory capacity in chronic or acute recurrent pancreatitis patients after total pancreatectomy (TP-IAT). KYSLECEL is a minimally …See details»
TRANS.00010 Autologous and Allogeneic Pancreatic Islet Cell …
Oct 1, 2024 Kyslecel is shipped back to the hospital in an IV bag for intraportal infusion and has a 6-hour expiration time. A variety of tissue sources, methods of islet isolation and …See details»
Orgenesis Announces Agreement to Acquire Koligo Therapeutics, …
Sep 29, 2020 48129.xChtIqk0O3DeQw1F0JuR1B4vwWsCwax2JCAnWUkF3nc.vkofcsV3QwHtGm8Mo978uydssgJtiNtCU39oLDlyjFq9QBxHygQCQY0vWA …See details»
KYSLECELâ„¢ with 24-hour expiration time improves access to
LOUISVILLE, Ky., July 16, 2019 /PRNewswire/ -- Koligo Therapeutics, Inc. announced that it has made KYSLECEL (autologous pancreatic islets) with a 24-hour expiration time available …See details»